Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.34 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.34 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 3/20 | 0.33 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605209 | 0.75 | PTGS1 (0.36) | TSHRLTB4RHPGDCETPALOX15 | |
| SCHEMBL7608675 | 0.74 | CETP (0.36) | TSHRCETPALOX15KMT2A | |
| SCHEMBL7610496 | 0.74 | CETP (0.35) | TSHRCETPKMT2A | |
| SCHEMBL7610525 | 0.73 | MAPK8 (0.40) | AKR1B1LTB4RHPGDPTGER1PTGER4 | |
| SCHEMBL7606964 | 0.73 | AKR1B1 (0.42) | AKR1B1TSHRLTB4RHPGDCETP | |
| SCHEMBL7604452 | 0.73 | CETP (0.37) | TSHRCETPALOX15KMT2A | |
| SCHEMBL7605064 | 0.72 | KDM4E (0.46) | AKR1B1PTGER1PTGER4PTGER3PTGER2 | |
| SCHEMBL7609236 | 0.72 | CETP (0.36) | TSHRCETP | |
| SCHEMBL8061507 | 0.70 | CXCL8 (0.50) | AKR1B1CAMK2AKMT2A | |
| SCHEMBL8059158 | 0.70 | CXCL8 (0.44) | AKR1B1CAMK2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| JP-2002514160-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | claimed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |